Study S001444

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07775846
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 820
Start: 2026-09-01
Primary completion: 2029-02-28
Lead sponsor: Huijie Zhang
Conditions: Type 2 Diabetic Kidney Disease
Interventions: DRUG:empagliflozin; DRUG:Finerenone; DRUG:Mazdutide; DRUG:Finerenone Placebo; DRUG:Mazdutide Placebo; DRUG:Angiotensin Receptor Blocker (ARB)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6 [Baseline and Month 6]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.